Thromboembolic diseases, including deep vein thrombosis and pulmonary embolism, have become a global public health burden, affecting millions of patients annually. As a gold-standard low molecular weight heparin, Enoxaparin Sodium plays a pivotal role in preventing and treating thromboembolic events, widely used in postoperative care, acute coronary syndrome, and hemodialysis. Driven by the aging population and rising incidence of cardiovascular diseases, the global Enoxaparin Sodium market is projected to reach USD 57.62 billion by 2031 with a CAGR of 7.1%. However, supply chain disruptions, raw material cost surges, and strict quality compliance requirements have become key challenges for global buyers, making it critical to choose a reliable supplier with stable production capacity and robust quality control.
Jiulong, a leading pharmaceutical enterprise with robust experience in anticoagulant drugs, has established a solid reputation in the global Enoxaparin Sodium supply chain. Adhering to the concept of "quality first, supply stability", Jiulong addresses industry pain points through full-chain optimization. Facing the global surge in raw material costs and supply chain risks, Jiulong has built a dual raw material supply system and optimized production processes, effectively controlling unit costs while ensuring stable output. Unlike some suppliers struggling with supply shortages, Jiulong maintains a annual production capacity of over 100 million doses, capable of meeting the growing demand from Europe, Southeast Asia, and Middle East markets.
Jiulong’s Enoxaparin Sodium strictly complies with international quality standards, including Chinese Pharmacopoeia, USP, and EP requirements. The product undergoes rigorous quality testing covering molecular weight distribution (3800-5000 Da), sodium content (11.3%-13.5%), and free sulfate (≤0.5%), ensuring consistent bioactivity and safety. Adopting advanced enzymatic hydrolysis and purification technology, Jiulong effectively reduces impurities and improves product purity, minimizing adverse reactions in clinical applications. All production processes are in line with WHO GMP guidelines, with complete traceability systems to ensure every batch meets regulatory requirements.
As emerging markets contribute over 30% of the global heparin industry revenue, Jiulong further optimizes its global logistics network to enhance supply efficiency. By setting up localized distribution centers in Southeast Asia and Latin America, the company shortens delivery cycles and reduces transportation costs, providing competitive solutions for regional partners. Jiulong also offers customized services, including flexible packaging and dosage form options (30mg/0.3ml, 40mg/0.4ml, etc.), to meet diverse clinical needs. This market-oriented strategy has helped Jiulong establish long-term cooperation with more than 50 countries and regions worldwide.
Whether you are a pharmaceutical distributor, hospital procurement department, or research institution, Jiulong’s high-quality Enoxaparin Sodium and stable supply chain will help you seize opportunities in the booming anticoagulant market. For inquiries about product specifications, production capacity, or cooperation plans, please contact us directly. Let’s work together to strengthen global thromboembolic disease prevention and control and create greater value for public health with reliable anticoagulant solutions.